CSPCY (CSPC Pharmaceutical Group) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

What is CSPC Pharmaceutical Group LT-Debt-to-Total-Asset?

CSPC Pharmaceutical Group CSPCY +8.17% 78 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates CSPCY with a GF Score™ of 78/100 and a GF Value™ of $3.12 (Modestly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CSPC Pharmaceutical Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

CSPC Pharmaceutical Group's long-term debt to total assets ratio increased from Dec. 2024 (0.00) to Dec. 2025 (0.00). It may suggest that CSPC Pharmaceutical Group is progressively becoming more dependent on debt to grow their business.

CSPC Pharmaceutical Group (OTCPK:CSPCY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CSPC Pharmaceutical Group LT-Debt-to-Total-Asset Related Terms

CSPC Pharmaceutical Group LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group LT-Debt-to-Total-Asset Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

0.00

CSPC Pharmaceutical Group Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

78GF Score

CSPC Pharmaceutical Group Ltd CSPCY

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CSPC Pharmaceutical Group LT-Debt-to-Total-Asset Calculation

CSPC Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	25.655	/	6630.213
	=	0.00

CSPC Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	25.655	/	6630.213
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

CSPC Pharmaceutical Group (CSPCY) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CSPC Pharmaceutical Group and its competitors.

Is CSPC Pharmaceutical Group's LT-Debt-to-Total-Asset too high?

CSPC Pharmaceutical Group's current LT-Debt-to-Total-Asset is 0.00. Overall, CSPC Pharmaceutical Group has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CSPC Pharmaceutical Group's LT-Debt-to-Total-Asset compare to LLY and JNJ?

CSPC Pharmaceutical Group's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CSPC Pharmaceutical Group stock overvalued right now?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.12, compared to a current price of $3.84 — trading 23.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. CSPC Pharmaceutical Group's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $3.84 is trading 23.1% above its estimated GF Value™ of $3.12. GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.

Key valuation signals for CSPCY:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $3.12 vs. price of $3.84 (23.1% above fair value)
GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies HKSE:07630 HKSE:02630 HKSE:01666 HKSE:01643 LLY JNJ ABBV XSWX:ROP MRK XSWX:NOVN LSE:AZN OCSE:NOVO B AMGN GILD PFE BMY LSE:GSK XPAR:SAN TSE:4519 XTER:BAYN

Other Exchanges CHJTF:USA 01093:Hong Kong CVG:Germany

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035

Website https://www.cspc.com.hk

CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.

78GF Score

Get the complete analysis for CSPCY

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84

Price

$3.12

GF Value

View CSPCY Analysis

See LT-Debt-to-Total-Asset data for all stocks →